Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing